• Sirohi B, Powles R, Lawrence D., Kulkarni S., Hollis H., Heming D., Sankpal S., Patel G., Singhal S., Treleaven J. Mehta J. An Open, Randomized, Controlled, Phase II, Single Centre, Two-Period Cross Over Study To Compare the Quality of Life (QoL) and Toxicity Experienced on PEG Interferon (P-IFN) with Interferon-a2b (IFN) in Patients with Multiple Myeloma (MM) Maintained on a Steady Dose of IFN- Annals of Oncology 2007 Aug;18(8):1388-94.May/June 2007.
  


• Sirohi B, Powles R, Morgan G, Treleaven J, Kulkarni S, Horton C, Saso R, Rolfe D, Cook G, Shaw C, Wass J. Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study. Bone Marrow Transplant. 2007 Jan;39(2):115-20. Epub 2006 Dec 4.
  


• Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006 Sep;20(9):1467-73. Epub 2006 Jul 20
  


• Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol. 2005 May 20;23(15):3412-20. Epub 2005 Apr 4
  


• Brian GM Durie 1 , Robert A Kyle 2,Andrew Belch 3 , William Bensinger 4 , Joan Blade 5 , Mario Boccadoro 6 , J Anthony Child 7 , Raymond Comenzo 8 , Ben Djulbegovic 1 , Dorotea Fantl 9 , Gosta Gahrton 10 , Jean Luc Harousseau 11 , Vania Hungria 12 , Douglas Joshua 13 , Heinz Ludwig 14 , Jayesh Mehta 15 , Angelina Rodrique Morales 16 , Gareth Morgan 16 , Amara Nouel 17 , Martin Oken 18 , Raymond Powles 19 , David Roodman 20 Jesus San Miguel 21 , Kazuyuki Shimizu 22 , Seema Singhal 15 , Bhawna Sirohi 19 , Peter Sonneveld 23 , Guido Tricot 24 and Brian Van Ness 25. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation 1 . The Hematology Journal (2003) 4, 379-398.
  


• S Kulkarni, R Powles, B Sirohi, J Treleaven, R Saso, C Horton, A Atra, M Ortin, C Rudi n, S Goyal, S Sankpal. Graft-Versus-Host Disease. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplantation (2003) 32, 165-170.
  


• Paul Mitchel,. MBBS, Fook-Thean Lee, PhD 2 , Cathrine Hall, BSc 2 , Angela Rigopoulos, MSc 2 , Fiona E. Smyth, BSc 2, Anne-Marie Hekman, PhD 3, Gijs M van Schijndel, PhD 4 , Ray Powles< PhD 5. Targeting Primary Human Ph +  B-Cell Precursor Leukemia-Engrafted SCID Mice Using Radiolabeled Anti-CD19 Monoclonal Antibodies. Leukemia Xenografts. Mitchell et al. 1105.
  


• 1084 Elnenaei MO, Gruszka-Westwood AM, A ’Hernt R, Matutes E, Sirohi B, Powles R, Catovsky D. Gene abnormalities in multiple myeloma; the relevances of TP53, MDM2, and CDKN2A. Haematologica 88: 529-537, 2003 .
  


• Sirohi B, Powles R, Singhal S, Kulkarni S, Rudin C, Treleaven J, Saso R, Horton C, and Mehta J. Prognostic factors at the time of autotransplantation with 200 mg/m 2 melphalan : a single-centre study of 451 meyloma (MM) patients. Abstact (247) presented at the British Society for Haematology, Glasgow U.K. 7-9 th April, 2002. BJH, Vol 121, Supplement 1 May 2003.

Parkside Oncology Clinic